Sodium-glucose cotransporter 2 inhibitors(SGLT2i)have emerged as a revolutionary class of antidiabetic agents with demonstrated benefits extending beyond glycemic control.Dedicated renal outcome trials of SGLT2i have ...Sodium-glucose cotransporter 2 inhibitors(SGLT2i)have emerged as a revolutionary class of antidiabetic agents with demonstrated benefits extending beyond glycemic control.Dedicated renal outcome trials of SGLT2i have shown impressive renal protective effects,regardless of diabetes status.[1–3]In the CREDENCE study,canagliflozin led to a 30%reduction(P<0.001)in the primary composite renal outcome vs.placebo in patients with type 2 diabetes(T2D)and albuminuric chronic kidney disease(CKD).[1]The DAPA-CKD trial further expanded the evidence of the renal benefits of SGLT2i using dapagliflozin to CKD patients with and without T2D.In DAPA-CKD,dapagliflozin reduced the primary composite renal outcome by 39%(P<0.001).[2]Similar findings were seen with empagliflozin in the EMPA-KIDNEY trial,which included CKD patients with lower estimated glomerular filtration rate(eGFR,down to a lower limit of 20 mL·min^(−1)·1.73 m^(−2)),a proportion of which had normoalbuminuria,compared with DAPA-CKD;the primary composite renal outcome was reduced by 28%(P<0.001).[3]展开更多
基金funded by National Nature Science Foundation of China(Nos.82170727,81870468,and 82270761)Star Program of Shanghai Jiao Tong University,Key medical and industrial projects(No.YG2023ZD21)+2 种基金China International Medical Exchange Foundation(No.Z-2017-26-2202-2)Shanghai Research Center for Endocrine and Metabolic Diseases(No.2022ZZ01002)National Key Research and Development Program of China(No.2023YFC2411802).
文摘Sodium-glucose cotransporter 2 inhibitors(SGLT2i)have emerged as a revolutionary class of antidiabetic agents with demonstrated benefits extending beyond glycemic control.Dedicated renal outcome trials of SGLT2i have shown impressive renal protective effects,regardless of diabetes status.[1–3]In the CREDENCE study,canagliflozin led to a 30%reduction(P<0.001)in the primary composite renal outcome vs.placebo in patients with type 2 diabetes(T2D)and albuminuric chronic kidney disease(CKD).[1]The DAPA-CKD trial further expanded the evidence of the renal benefits of SGLT2i using dapagliflozin to CKD patients with and without T2D.In DAPA-CKD,dapagliflozin reduced the primary composite renal outcome by 39%(P<0.001).[2]Similar findings were seen with empagliflozin in the EMPA-KIDNEY trial,which included CKD patients with lower estimated glomerular filtration rate(eGFR,down to a lower limit of 20 mL·min^(−1)·1.73 m^(−2)),a proportion of which had normoalbuminuria,compared with DAPA-CKD;the primary composite renal outcome was reduced by 28%(P<0.001).[3]
